PD-1 antibody camrelizumab plus apatinib and SOX as first-line treatment in patients with AFP-producing gastric or gastro-esophageal junction adenocarcinoma (CAP 06): a multi-center, single-arm, phase 2 trial

Authors: Yakun Wang, Jialin Lu, Xiaoyi Chong, Chang Wang, Xiaofeng Chen, Zhi Peng, Yanhong Gu, Yizhuo Wang, Xicheng Wang, Jian Li, Jifang Gong, Changsong Qi, Jiajia Yuan, Zhihao Lu, Ming Lu, Jun Zhou, Yanshuo Cao, Yang Chen, Cheng Zhang, Zhiguo Hou, Hongyi Kou, Lin Shen, Xiaotian Zhang

Published: 2025-03-14

DOI: 10.1038/s41392-025-02193-z

Source: Full article

PD-1 antibody camrelizumab plus apatinib and SOX as first-line treatment in patients with AFP-producing gastric or gastro-esophageal junction adenocarcinoma (CAP 06): a multi-center, single-arm, phase 2 trial

Abstract